p53 protein overexpression and response to induction chemoradiation therapy in patients with locally advanced rectal adenocarcinorna

Annals of Surgical Oncology

Volumn 5, Issue 3, 1998, Pages 203-208

  Luna Perez, Pedro ^a,d   Arriola, Emma L ^c   Cuadra, Yvonne ^b   Alvarado, Isabel ^b   Quintero, Angelina ^c  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b HOSPITAL DE ONCOLOGÍA   (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^d NONE   (Mexico)

Author keywords

Colorectal cancer; Immunohistochemistry; P53; Radiotherapy; Surgery

Indexed keywords

FLUOROURACIL; PROTEIN P53;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PELVIS EXENTERATION; PROTEIN EXPRESSION; RECTUM ABDOMINOPERINEAL RESECTION; RECTUM CARCINOMA; SURGICAL TECHNIQUE;

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; BIOPSY; CHEMOTHERAPY, ADJUVANT; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS; REMISSION INDUCTION; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031839988     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02303772     Document Type: Article

References (31)

1. Jass JR, Atkin WS, Cuzick I, et al. The grading of rectal cancer: histological perspectives and a multivariate analysis of 447 cases. Histopathology 1986;10:437-59.
2. Baker SJ, Preisinger AC, Jessup JM, et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 1990;50:7717-22.
3. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992;70:523-6.
4. El-Deiry WS, Tokino T, Velculescu, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
5. Kastan MB, Onyerwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-11.
6. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54;4855-78.
7. Yonish RE, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M, Wild-type p53 induces apoptosis of mycloid leukaemic cells that is inhibited by interleukin-6. Nature 1991;353:345-7.
8. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74:957-67.
9. Harris CC, Hollstein M. Clinical implications of the p53 tumor suppressor gene. N Engl J Med 1993;329:1318-27.
10. Marshall CJ. Tumor suppressor genes. Cell 1991;64:313-26.
11. Horio Y, Takahashi T, Kuroishi T, et al. Prognostic significance of p53 mutations and 3p deletion in primary resected non-small cell lung cancer. Cancer Res 1993;53:1-4.
12. Sarkis AS, Bajorin DF, Reuter VE, et al. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol 1995;13:1384-90.
13. Zeng ZS, Sarkis AS, Zhang ZF, et al. P53 nuclear overexpression: An independent predictor of survival in lymph node-positive colorectal cancer patients. J Clin Oncol 1994;12:2043-50.
14. Hamelin R, Laurent-Puig P, Olsschwang S, et al. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 1994;106:42-8.
15. Flamini G, Curigliano G, Ratto C, et al. Prognostic significance of cytoplasmic p53 overexpression in colorectal cancer, An immunohistochemical analysis. Eur J Cancer 1996;32A:802-6.
16. Öfner D, Maeir H, Riedmann B, et al. Immunohistochemically detectable p53 and mdm-2 oncoprotein expression in colorectal carcinoma: prognostic significance. JCP: Clin Mol Pathol 1995; 48:M12-M16.
17. Scott N, Sagar P, Stewart J, Blair GE, Dixon MF, Quirke P. p53 in colorectal cancer: clinicopathological correlation and prognostic significance. Br J Cancer 1991;63:317-9.
18. Hamada M, Fujiwara T, Hizuta A, et al. The p53 is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers. J Cancer Res Clin Oncol 1996;122:360-5.
19. Sanchez W, Luna-Perez P, Alvarado I, Labastida S, Herrera L. Modified clearing technique to identify lymph node metastases in post-irradiated surgical specimens from rectal adenocarcinoma. Arch Med Res (Mex) 1996;27:31-6.
20. UICC. TNM Classification of Malignant Tumours. Berlin: Springer-Verlag, 1987.
21. Kerr JF, Winterford CM, Harmon BV. Apoptosis: its significance in cancer and cancer therapy. Cancer 1994;73:2013-23.
22. Brett MC, Pickard M, Green B, Howel-Evans A, Smith D, Kinsella A, Poston G. p53 protein overexpression and response to biomodulated 5-fluorouracil chemotherapy in patients with advanced colorectal cancer. Eur J Surg Oncol 1996;22:182-5.
23. Lin DL, Chang C. p53 is a mediator for radiation-repressed human TR2 orphan receptor expression in MCF-7 cells, a new pathway from tumor suppressor to member of the steroid receptor super-family. J Biol Chem 1996;271:14649-52.
24. Pickard M, Dive C, Kinsella AR. Differences in resistance to 5-FU as a function of cell cycle delay not apoptosis. Br J Cancer 1995; 72:1389-96.
25. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB, Roth JA. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 1994;54:2287-91.
26. Luna-Perez P, Rodriguez D, Ortiz N. Labastida S, Delgado S, Herrera L. Sphincter-saving surgery with and without preoperative radiation therapy as treatment for adenocarcinoma of the mid-rectum. Surg Oncol 1995;4:223-9.
27. Rasbridge SA, Gillett CE, Seymour AM, Patel K, Richards MA, Rubens RD, Millis RR. The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma. Br J Cancer 1994;70:335-41.
28. Diez M, Enriquez JM, Camuñas J, et al. Prediction of recurrence in B-C stages of colorectal cancer by p53 nuclear overexpression in comparison with standard pathological features. Eur J Surg Oncol 1993;21:635-9.
29. Benhattar J, Cerottini JP, Saraga E, Metthez G, Givel JC. p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Int J Cancer 1996;69:190-2.
30. Shouthern E. Detection of specific sequences among DNA fragments separated by electrophoresis, J Mol Biol 1975;98:503-17.
31. Maniatis T, Fritsch E, Sambrock J. Molecular cloning: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor. 1982;9:31-55.